Lucid picks up Rare Disease and Orphan Drugs trophy for Hidradenitis suppurativa (HS) project

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted in London earlier this week.

The agency’s ‘EIDON’ project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).

PMEA’s judges said:

“The Eidon project took a whole programme approach, building awareness from zero to create a network and care delivery infrastructure.

“It is a clearly-structured entry with key behaviours and outcomes defined and measured, and most important, an impressive number of patients were treated.”

Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases.


 

Tags:
0 Comments

Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2018 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?